フィルターを表示する
リソースの種類
フィルターで絞り込む リソースの種類
Pathologies
フィルターで絞り込む Pathologies
Technologies
フィルターで絞り込む Technologies
Instruments
フィルターで絞り込む Instruments
12 検索結果
並び替え:

Challenges in Implementing Capillary Electrophoresis for Immunotyping

ウェビナー
3月. 29, 2023

Educational Webinar with Dr. Jack Maggiore from Loyola University Medical Center in Chicago, IL

Modern Approach to Screening for Monoclonal Gammopathies Using Digital Workflows

ウェビナー
2月. 23, 2023

Educational Webinar with Dr. Mark Zaydman from Washington University School of Medicine in St. Louis, MO

Sebia acquires Zeus Scientific

プレスリリース
10月. 12, 2022

The strategic acquisition reinforces Sebia’s product portfolio & strategy in autoimmunity

Performance of Immunotyping vs. Immunofixation for the Detection of Monoclonal Gammopathies

ウェビナー
9月. 30, 2022

Educational Webinar with Katie Thoren, PhD, Memorial Sloan Kettering Cancer Center

Sebia and Metafora biosystems form strategic partnership to develop advanced in vitro diagnostics

プレスリリース
9月. 30, 2022

Sebia to acquire a minority stake in Metafora biosystems.

Multiple Myeloma clinical cases for diagnosis and monitoring according to latest IMWG recommendations

ウェビナー
9月. 30, 2022

Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD

Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab

出版物
9月. 30, 2022

Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.